Inceptionr LLC Has $664,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Inceptionr LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 8,533 shares of the medical device company’s stock after buying an additional 1,324 shares during the quarter. Inceptionr LLC’s holdings in DexCom were worth $664,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Jennison Associates LLC increased its position in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after purchasing an additional 710,858 shares in the last quarter. Groupama Asset Managment increased its position in DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after purchasing an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock valued at $219,716,000 after acquiring an additional 91,051 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Canaccord Genuity Group upped their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Trading Down 2.1 %

NASDAQ:DXCM opened at $77.84 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $30.42 billion, a price-to-earnings ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28. The firm has a fifty day simple moving average of $84.83 and a two-hundred day simple moving average of $76.96. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.